CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 2018—One year after its establishment, the Blood Profiling Atlas in Cancer consortium announced the public release of an initial dataset aimed at speeding the development and approval of liquid biopsy technologies. The dataset resides in the BloodPAC data commons and was developed to deepen the understanding of a patient’s cancer and accelerate the development of liquid biopsy technology to improve the outcomes of patients with cancer. BloodPAC worked with the FDA’s Center for Devices and Radiological Health to identify an initial set of 11 minimum technical data elements for preanalytical fields. These criteria are established within the data commons to facilitate cross-analysis and improve the usability and reliability of the data for liquid biopsy research. The 11 data elements are metadata fields that must accompany the submission of all future blood profiling dataset contributions from consortium members to the BloodPAC data commons. BloodPAC will focus its second year on establishing the next layer of MTDEs to define and support other steps in assay development.
BloodPAC, 202-725-2553